We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Designing Lipid Nanoparticle Systems for COVID-19 Vaccines

Designing Lipid Nanoparticle Systems for COVID-19 Vaccines content piece image

Lipid nanoparticle (LNP) technology is increasingly enabling the clinical potential of genetic drugs. By packaging the nucleic acid polymer in well-defined nanoparticles, LNPs protect the nucleic acid payload in vivo and facilitate intracellular delivery following uptake into target cells by endocytosis.

A notable example is the development of LNP mRNA vaccines, including the Pfizer/BioNTech COVID-19 vaccine B162b2, which is playing a leading role in the global response to the COVID-19 pandemic.

In this webinar, Pieter Cullis, Ph.D. FRSC, FNAI, a professor in the Department of Biochemistry and Molecular Biology at the University of British Columbia, and scientific director & CEO of NanoMedicines Innovation Network, will explore the design of LNP systems and discuss the design of the LNP used in the Pfizer/ BioNTech COVID-19 vaccine

Attend this webinar to discover:

  • An overview of how LNP systems work
  • How LNP delivery systems are designed
  • The efforts that led to the Pfizer/ BioNTech BNT162b2 COVID-19 vaccine
Pieter Cullis
Pieter Cullis
Professor, Biochemistry Department, University of British Columbia